Oracle and AstraZeneca agree to explore AI in healthcare

Oracle announced the agreement on Oct. 20, 2026; its press release lists Austin, Texas, and Abu Dhabi in the dateline.[1] Oracle says the agreement is non-binding and that the companies plan to explore selected use cases.[1] The stated aim is to accelerate the journey from medicine discovery to patient care.[1]

The companies will explore using AI and real-world data to help clinicians identify patients eligible for clinical trials, generate evidence faster and bring research insights into everyday care.[1] Oracle says applications and AI could help care teams find eligible patients earlier and more easily, potentially improving clinical-trial efficiency and success.[1] Oracle describes patient recruitment as one of the largest obstacles in clinical trials.[1] It also says greater access to trials for patients in need could result.[1]

Oracle lists oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases as areas the companies could explore initially.[1] Oracle says the collaboration is expected to bring together AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, analytics and clinical workflow capabilities.[1] For teams evaluating the proposal, the breadth of possible disease areas is not evidence that all of them will be included in a program; Oracle describes them as areas the companies could explore.[1]

A Wall Street Journal quote says the first program will focus on hypertension care and clinical research in Abu Dhabi, and that the partners aim to test ways to connect research directly to clinical workflows.[2] Oracle’s stated ambition is to use AI to connect learning across science, clinical trials and everyday care.[1] Oracle also says the opportunity is to accelerate research, connect more patients to trials and bring relevant insights into care faster.[1]